Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey,J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey,S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Marquez-Rodas, J.-J. Grob, M.O. Butler,M.R. Middleton, M. Maio, V. Atkinson, P. Queirolo, R. Gonzalez, R.R. Kudchadkar,M. Smylie, N. Meyer, L. Mortier, M.B. Atkins, G.V. Long, S. Bhatia, C. Lebbé,P. Rutkowski, K. Yokota, N. Yamazaki, T.M. Kim, V. de Pril, J. Sabater, A. Qureshi,J. Larkin, and P.A. Ascierto, for the CheckMate 238 Collaborators*

 

Allegati:
Scarica questo file (63.Adjuvant Nivolumab nejm.pdf)63.Adjuvant Nivolumab nejm.pdf[ ]275 kB